Menu

MedTech and Pharma News



Actavis Faces Wait Until 2027 On US Pennsaid
Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing...
Scrip - October 15, 2019
Takeda Offloads Emerging Market OTCs to Acino
Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay...
HBW Insight - October 15, 2019
Mylan Fails To Unblock Path On German Glatiramer
A German higher regional court has upheld an injunction barring Mylan from marketing its Clift rival to Teva’s Copaxone 40mg/ml...
Scrip - October 15, 2019
India's USV Reveals Investment Plans
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its...
Scrip - October 15, 2019
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and...
Scrip - October 15, 2019
Drug/Device Combinations: Shock For Pharma As It Seeks Notified Body Resources Too
With the delivery of drugs via medical devices commonplace now, and the introduction of new EU rules for these products...
Medtech Insight - October 15, 2019
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around...
Scrip - October 15, 2019
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino For $200m
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around...
Scrip - October 15, 2019
QUOTED. 15 October 2019. Sandi Schaible
All devices on the European market will require pre-clinical testing if their design history files do not meet certain requirements...
Medtech Insight - October 15, 2019

Drug/Device Combinations: Shock For Pharma As It Seeks Notified Body Resources Too
With the delivery of drugs via medical devices commonplace now, and the introduction of new EU rules for these products...
Medtech Insight - October 15, 2019
QUOTED. 15 October 2019. Sandi Schaible
All devices on the European market will require pre-clinical testing if their design history files do not meet certain requirements...
Medtech Insight - October 15, 2019

Actavis Faces Wait Until 2027 On US Pennsaid
Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing...
Scrip - October 15, 2019
Mylan Fails To Unblock Path On German Glatiramer
A German higher regional court has upheld an injunction barring Mylan from marketing its Clift rival to Teva’s Copaxone 40mg/ml...
Scrip - October 15, 2019
India's USV Reveals Investment Plans
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its...
Scrip - October 15, 2019
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and...
Scrip - October 15, 2019
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino For $200m
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around...
Scrip - October 15, 2019
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around...
Scrip - October 15, 2019

US FDA Panel To Assess Possible Mortality Imbalance For Shionogi's cUTI Candidate Cefiderocol
Although cefiderocol demonstrated safety and efficacy in a pivotal trial for complicated urinary tract infections, there was a mortality imbalance...
Pink Sheet - October 14, 2019
Possible Mortality Imbalance For Shionogi's Cefiderocol On US FDA Panel Agenda
Although cefiderocol demonstrated safety and efficacy in a pivotal trial for complicated urinary tract infections, there was a mortality imbalance...
Pink Sheet - October 14, 2019
DOJ Casting Wider Net In Pharma Kickback Probes
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked...
Pink Sheet - October 14, 2019
RWE: Comparators, Therapeutic Area May Be Key For Trial Replication
It may be easier to use observational study data to replicate randomized controlled trial results in certain therapeutic areas or...
Pink Sheet - October 14, 2019
UK Signs First No-Deal Brexit Ferry Contracts
If the UK leaves the EU without a deal at the end of this month, pharmaceutical companies will be able...
Pink Sheet - October 14, 2019
Canadian Originators Are Free To Try Again
Having unsuccessfully asserted a patent under the previous legal framework in Canada does not preclude an originator from trying again...
Pink Sheet - October 14, 2019
Yet Another Myeloma CAR-T Therapy Makes It Onto EMA’s PRIME
Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet...
Pink Sheet - October 14, 2019
UK Tackles GCP Concerns Over Electronic Health Records
As NHS Trusts switch from paper-based to electronic health records, concerns have arisen about the compatibility of EHR systems with...
Pink Sheet - October 14, 2019
EU Accelerated Assessment Tracker
Roche has secured accelerated assessment at the European Medicines Agency for its new immunosuppressant, satralizumab. The outcomes of five other...
Pink Sheet - October 14, 2019

GSK's Hal Barron On R&D Progress At Two-Year Mark
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices...
In Vivo - October 14, 2019
PureTech’s Problem-Solving Skills Target The BIG Picture
PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs...
In Vivo - October 14, 2019

PE consortium buys Nestle Skin Health for CHF10.2bn; re-brands as Galderma
Following initial discussions started in May 2019, a private equity consortium--led by EQT VIII fund, and including Luxinva (a subsidiary of Abu Dhabi Investment Authority), PSP Investments, and other institutional investors--acquired Nestle SA's Nestle Skin Health SA (OTC and prescription skin-care), for CHF10.2bn ($10.23bn).
Strategic Transactions - October 11, 2019

Takeda Offloads Emerging Market OTCs to Acino
Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay...
HBW Insight - October 15, 2019
Back to the top Back to the top